Overview

TAS-OX for Refractory Metastatic Colon Cancer

Status:
Completed

Trial end date:
2020-06-02

Target enrollment:

Participant gender:

Summary

This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Yale University

Treatments:

Oxaliplatin
Trifluridine